WiremapS2 — Revenue Analysis
Current ARR
$1.4M
Up from $680K 12 months ago
Net Revenue Retention
116%
Above SaaS benchmark of 110%
Avg Contract Value
$38K
Range $18K–$120K — wide variance
Deals from Outbound
0%
100% from founder network
12-Month Revenue Trend
Period
New MRR
Expansion
Churn
Net MRR
Month 1–3
+$18K
+$4K
-$2K
+$20K
Month 7–9
+$36K
+$12K
-$3K
+$45K
Month 10–12
+$22K
+$18K
—
+$40K
12-Month Total
+$100K
+$42K
-$5K
+$137K
What this trend shows: Revenue growth is real and healthy. Expansion revenue is accelerating — customers are buying more over time, validating the product. Churn is minimal. The pattern underneath it is the problem: every new MRR line item originated from the founder's existing relationships, not a repeatable acquisition channel. That single fact is what a Series A investor will focus on.
Revenue by source — last 12 months
Founder direct relationship58%
Warm referral from existing customer32%
Conference or event meeting10%
Outbound generated0%
Closed-won by buyer segment
Independent physician practices45%
Regional hospital systems30%
Specialty clinics18%
Other healthcare organisations7%
WiremapS3 — Pipeline Audit · S4 — ICP Validation
Pipeline Conversion Rates
Qualified opportunities
65%
What the funnel is hiding: 28% close rate looks strong. But the 65% qualification rate is inflated — every lead came from a warm relationship. A cold-sourced pipeline qualifies at 15 to 20%, meaning the real close rate on net-new prospects is unknown. This is the critical gap investors will probe.
S4 — ICP Validation Against Closed-Won Data
Stated ICP — too broad
"Healthcare organisations that need to improve patient engagement." This describes approximately 900,000 entities in the US — hospitals, clinics, practices, insurance companies, health systems, and dozens of sub-segments. This is not an ICP. It is a market description. It produces no clear outbound starting point.
What closed-won data shows
Real pattern in closed-won: independent physician practices and regional hospital systems under 5 hospitals, where CMO or VP of Patient Experience owns the decision. 3 to 5 decision makers. $18K to $60K deal range. 60 to 90 day sales cycle. This is the actual ICP — and it can be targeted with outbound.
WiremapS5 — Revenue Due Diligence Scorecard
Revenue Dimensions — Series A Readiness
Net Revenue Retention116% — above benchmark. Customers expand. Product works.
9/10
Product-Market Fit SignalStrong satisfaction, low churn, word-of-mouth growth
8/10
ARR Growth Rate2x in 12 months — strong but driven by network not motion
6/10
Average Contract Value$38K average but wide variance — pricing not systematised
5/10
Repeatable Motion0 outbound-sourced deals. No repeatable acquisition channel.
1/10
Sales Team IndependenceAll deals require founder. No AE producing independently.
2/10
ICP PrecisionStated ICP too broad. Real ICP buried in closed-won data.
2/10
Investor GTM NarrativeStrong product story. Weak motion story. Investor Q unanswered.
4/10
WiremapS6 — GTM Assessment · S7 — Investor Narrative
What is working
✦
Referral engine is strong32% of revenue came from existing customer referrals. NRR of 116% means customers actively expand. This is a genuine growth lever — but it needs to be systematised, not relied upon passively.
✦
Conference channel has signal10% of revenue from event-sourced meetings without focused investment. Healthcare conferences — HIMSS, ViVE — are where the ICP is concentrated. This channel has produced results without being properly resourced.
✦
Product retention is exceptionalNear-zero churn and strong customer satisfaction scores. The product solves a real problem and customers know it — they stay and they expand.
What is not working
⚑
No outbound motion existsZero outbound-sourced pipeline. Whether the product can be sold to a cold buyer has never been tested. This is the central question of Series A readiness.
⚑
Pricing is inconsistentACV ranges from $18K to $120K with no clear rationale. Pricing is negotiated deal by deal rather than anchored to a defined value metric. Investors will flag this immediately.
⚑
Channel strategy undefinedDirect, partner, and self-serve have all been attempted. None has been chosen as the primary motion. Resources spread across three approaches produces worse results than focused investment in one.
S7 — The Investor Narrative Gap
Investor question
Current answer
Answer after 90-day plan
"What is your repeatable motion?"
We have grown through relationships
LinkedIn outbound to CMOs at independent practices producing 3 new conversations per week — pipeline data available
"Who is your ICP?"
Healthcare organisations that need patient engagement
CMOs at independent physician practices (5–50 physicians) and regional health systems — 75% of revenue from this segment, validated by closed-won analysis
"What is your payback period?"
We haven't calculated it formally
14 months at current ACV and CAC. Pathway to 10 months with ACV increase to $45K average
"Why are you winning?"
The product is good
HIPAA compliance + real-time engagement + EHR integration — the only platform in the independent practice segment delivering all three without a 6-month implementation
WiremapS8 — ROI & Key Takeaways
The cost of raising without a repeatable motion
Investors who identify the "founder-only pipeline" pattern price the risk into the term sheet — typically a lower valuation or more aggressive milestone requirements.
Valuation at Risk
0.5–1x
Typical ARR multiple discount when Series A investors cannot see a repeatable acquisition motion in the data room
Revenue Left Uncaptured
$540K
Estimated annual ARR from a structured outbound motion reaching the real ICP at 3 new deals per month at $38K ACV
NRR Advantage to Protect
116%
This metric is the strongest asset in the data room. Protecting it while fixing the acquisition gap changes the Series A valuation conversation entirely
The 5 specific things this diagnosis gives you
✦
A precise ICP from your own closed-won dataCMOs at independent physician practices (5–50 physicians) and regional health systems. Validated by 12 months of actual buying behaviour — not an assumption. This ICP can be targeted with outbound starting this week.
✦
A clear answer to the investor repeatable motion questionOne outbound-sourced closed deal before the Series A meeting changes every investor conversation. The 90-day plan is built to produce that deal before the raise begins.
✦
A systematised referral engine32% of revenue came from referrals without a formal process. A structured referral programme — asking every customer directly with a defined incentive — can double that contribution without any outbound cost.
✦
The investor narrative answers — before they askThe four investor questions most likely to expose the current gaps — now answered with data. The GTM narrative slide writes itself from the Section 7 table in this report.
⚑
The work this report has not doneDetailed outbound sequence copy for the healthcare buyer. Pricing model benchmarked against patient engagement competitors. Partner channel strategy for EHR vendors. Full Series A investor narrative deck. These require a deeper advisory engagement — covered in the post-report consultation.
WiremapS9 — 90-Day Pre-Series A Plan
The strategic goal of this 90-day plan: Demonstrate that the company can acquire a customer through outbound without the founder's personal relationship. One outbound-sourced closed deal before the Series A meeting changes every investor conversation that follows.
Write the precise ICP document from the closed-won analysis. Name the buyer title, company size, geography, and urgency trigger. Stop using "healthcare organisations" as a description — it produces no actionable outreach target.
Systematise the referral engine. Ask every existing customer directly: "Who else in your network has the same patient engagement problem?" Offer a structured referral incentive — service credit or a quarterly review session.
Build the investor GTM narrative using the updated ICP, NRR data, and closed-won pattern. Write the GTM slide before the pitch deck — the GTM story determines the valuation conversation.
Standardise pricing around a defined value metric — patient volume or practice size — so every deal is anchored to a consistent rationale rather than negotiated case by case.
Build the LinkedIn Sales Navigator search: CMO OR VP Patient Experience OR Chief Nursing Officer at independent physician practices (5–50 physicians) and regional health systems (1–5 hospitals) in the US. Target 400 contacts.
Build one outbound sequence — three touches. LinkedIn connection request, follow-up referencing a specific patient retention metric, final message offering a 20-minute call on improving patient re-engagement rates.
Send 20 connection requests per day. Track reply rate, conversation rate, and meeting rate weekly. Target: 5 outbound-sourced meetings in 30 days.
Register for HIMSS or ViVE conference. Book 10 meetings in advance with target ICP buyers. In-person conversations at healthcare conferences convert at 3 to 4 times the rate of cold outreach.
From the 5 outbound-sourced meetings in Phase 2, convert one to a closed deal before the Series A process begins. Even at $20K ACV, one outbound-sourced deal changes the investor narrative from "relationship-driven" to "emerging repeatable motion."
Document the outbound process that produced the deal as a repeatable playbook. This becomes evidence that Series A capital will be deployed into a process that works — not an experiment.
Brief 3 existing customers on the Series A raise and ask for reference calls with investors. NRR of 116% and strong customer satisfaction makes reference calls a significant fundraising asset.
WiremapS10 — Revenue Maturity Grid
| Dimension | L1 — No System | L2 — Early | L3 — Developing | L4 — Mature | L5 — Series A Ready |
|---|
| Repeatable Motion | ● | | | | |
| ICP Precision | | ● | | | |
| Outbound Capability | ● | | | | |
| Pricing Systematisation | | ● | | | |
| Channel Focus | | ● | | | |
| Investor GTM Narrative | | ● | | | |
| Net Revenue Retention | | | | | ● |
| Customer Satisfaction | | | | ● | |
| ARR Growth Rate | | | | ● | |
What this report has given you
A complete revenue picture showing where the business is genuinely strong — NRR, customer satisfaction, ARR growth — and where the Series A risk lives. The specific ICP derived from closed-won data: CMOs at independent practices and regional health systems. A gap analysis of the investor narrative with answers to the four questions every Series A investor will ask. A 90-day plan structured to produce one outbound-sourced closed deal before the raise — the single piece of evidence that changes the investor conversation.
The most important thing after reading this
Do not start the Series A process until one outbound-sourced deal has closed. Investors will ask. The 90-day plan produces that evidence in time. Sixty days of focused outbound before the raise is worth six months of fundraising momentum.